Document Detail


Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.
MedLine Citation:
PMID:  9636014     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of this study was to evaluate the antitumor activity of vinorelbine and oral estramustine phosphate in patients with metastatic, hormone-refractory prostate cancer. We evaluated the activity of this association using the following schedule: estramustine phosphate 600 mg/m2/day orally days 1-42 and vinorelbine 25 mg/m1 days 1, 8, 22, 29 cycles repeated every 56 days. Twenty-five patients were included in the study, 24 being evaluable for response and 25 for toxicity. Out of 5 patients with measurable disease, none had an objective response. Of the 24 assessable patients with bone metastases, 9 patients had a > or = 65% decline in pretreatment prostate-specific antigen (PSA) level, stable disease was observed in 10 and 5 patients progressed. Toxicities were minimal. Anemia was observed in 5 patients, alopecia in 4 and nausea and vomiting was observed in 6 patients. Anorexia and weight loss of more than 10% were observed in 2 patients. This combination is active and well tolerated in hormone-resistant prostate cancer. These results support the therapeutic strategy of combining agents that impair microtubule function.
Authors:
J Carles; M Domenech; A Gelabert-Mas; M Nogue; J M Tabernero; A Arcusa; I Guasch; A Miguel; J J Ballesteros; X Fabregat
Related Documents :
3887894 - Differences in cea values determined by eia and ria in patients with benign and maligna...
12664064 - Role of ca 15-3 in patients with biochemically suspected prostate cancer and multiple n...
15126814 - Granulomatous prostatitis linked to hla-drb1*1501.
10629644 - Comparison of cea, mca, ca 15-3 and ca 27-29 in follow-up and monitoring therapeutic re...
17000974 - First seizure presentation: do multiple seizures within 24 hours predict recurrence?
2818284 - Simple microphthalmos.
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study    
Journal Detail:
Title:  Acta oncologica (Stockholm, Sweden)     Volume:  37     ISSN:  0284-186X     ISO Abbreviation:  Acta Oncol     Publication Date:  1998  
Date Detail:
Created Date:  1998-07-02     Completed Date:  1998-07-02     Revised Date:  2009-05-12    
Medline Journal Info:
Nlm Unique ID:  8709065     Medline TA:  Acta Oncol     Country:  NORWAY    
Other Details:
Languages:  eng     Pagination:  187-91     Citation Subset:  IM    
Affiliation:
Uro-Oncology Unit, Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Spain. 90604@imas.imim.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / drug therapy*,  mortality,  secondary
Administration, Oral
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Drug Administration Schedule
Estramustine / administration & dosage,  adverse effects
Humans
Male
Middle Aged
Prostatic Neoplasms / drug therapy*,  mortality,  pathology
Survival Rate
Vinblastine / administration & dosage,  adverse effects,  analogs & derivatives
Chemical
Reg. No./Substance:
2998-57-4/Estramustine; 71486-22-1/vinorelbine; 865-21-4/Vinblastine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Growth hormone reduces mortality and bacterial translocation in irradiated rats.
Next Document:  Alterations of the immunoglobulin heavy chain locus in progressive B-cell lymphomas.